Elanco Animal HealthELAN -2.11%66 Days Payable is 57.62 as of Mar. 2026, which is 1% below its 10-year median of 58.11. GuruFocus rates ELAN with a GF Score™ of 66/100 and a GF Value™ of $15.58 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, Elanco Animal Health ranks worse than 68.08% on this metric.
The historical rank and industry rank for Elanco Animal Health's Days Payable or its related term are showing as below:
ELAN'
s Days Payable Range Over the Past 10 Years
Min: 47.43 Med: 58.11 Max: 79.22
Current: 59.42
During the past 11 years, Elanco Animal Health's highest Days Payable was 79.22. The lowest was 47.43. And the median was 58.11.
ELAN's Days Payable is ranked worse than 68.08% of 921
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs ELAN: 59.42
Elanco Animal Health's Days Payable
increased
from Mar. 2025 (56.11) to Mar. 2026 (57.62).
It may suggest that Elanco Animal Healthdelayed paying its suppliers.
Elanco Animal Health Days Payable Related Terms
Elanco Animal Health Days Payable Historical Data
* Premium members only.
The historical data trend for Elanco Animal Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elanco Animal Health Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Elanco Animal Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Elanco Animal Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health (ELAN) has a Days Payable of 57.62 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Elanco Animal Health and its competitors. This is near median its historical median of 58.11. Over the past decade, Elanco Animal Health's Days Payable has ranged from 47.43 to 79.22. According to the industry distribution chart, Elanco Animal Health ranks #627 out of 921 companies in the Drug Manufacturers industry, placing it in the top 68.1%.
Is Elanco Animal Health's Days Payable too high?
Elanco Animal Health's current Days Payable of 57.62 is near median its 10-year median of 58.11. Over the past 10 years, this metric has ranged from a low of 47.43 to a high of 79.22. The Drug Manufacturers industry median Days Payable is 90.69. Elanco Animal Health's value of 57.62 is 36.5% below this industry median. Based on the distribution chart, Elanco Animal Health ranks #627 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Elanco Animal Health has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's Days Payable compare to ALKS and HIMS?
According to the Drug Manufacturers industry distribution chart, Elanco Animal Health ranks #627 out of 921 companies for Days Payable. This places Elanco Animal Health in the lower half of its industry. The industry median Days Payable is 90.69. Elanco Animal Health's value of 57.62 is 36.5% below this benchmark. Historically, Elanco Animal Health's own Days Payable has ranged from 47.43 to 79.22 over the past decade. While the company's 10-year median is 58.11 vs. the industry median of 90.69, Elanco Animal Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elanco Animal Health's current Days Payable of 57.62 is 36.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Elanco Animal Health and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elanco Animal Health's current Days Payable is 57.62, which is near median its own 10-year median of 58.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.58, compared to a current price of $24.09 — trading 54.6% above its estimated fair value. The current Days Payable is 57.62, which is near median its 10-year median of 58.11 and 36.5% below the Drug Manufacturers industry median of 90.69. Elanco Animal Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current Days Payable is 57.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elanco Animal Health (ELAN) Overvalued in 2026?
Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued.
The current stock price of $24.09 is trading 54.6% above its estimated GF Value™ of $15.58.
GuruFocus considers Elanco Animal Health to be Significantly Overvalued.
Key valuation signals for ELAN:
Days Payable: 57.62 (near median its 10-year median of 58.11)
GF Value™: $15.58 vs. price of $24.09 (54.6% above fair value)
Industry Position: 36.5% below the Drug Manufacturers median (#627 of 921)
No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
66GF Score
Get the complete analysis for ELAN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELAN has been successfully added to your 
